These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30917706)

  • 1. Ramucirumab: the long and winding road toward being an option for mCRC treatment.
    Debeuckelaere C; Murgioni S; Lonardi S; Girardi N; Alberti G; Fano C; Gallimberti S; Magro C; Ahcene-Djaballah S; Daniel F; Fassan M; Prenen H; Loupakis F
    Expert Opin Biol Ther; 2019 May; 19(5):399-409. PubMed ID: 30917706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
    Diaz-Serrano A; Riesco-Martinez MC; Garcia-Carbonero R
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):585-95. PubMed ID: 27144874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of ramucirumab for the treatment of colorectal cancer.
    Noguerido A; Mulet-Margalef N; Matos I; Ros J; Argilés G; Élez E; Tabernero J
    Expert Opin Drug Saf; 2018 Sep; 17(9):945-951. PubMed ID: 30073902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with ramucirumab : outcomes in breast cancer.
    O'Sullivan Coyne G; Burotto M
    Expert Opin Biol Ther; 2014 Sep; 14(9):1351-60. PubMed ID: 25018016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging VEGF-receptor inhibitors for colorectal cancer.
    Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics of ramucirumab for metastatic colorectal cancer.
    Zeichner SB; Kohn CG; Goldstein DA
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):733-745. PubMed ID: 27828732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.
    Gambardella V; Tarazona N; Cejalvo JM; Roselló S; Cervantes A
    Expert Opin Drug Metab Toxicol; 2016; 12(4):449-56. PubMed ID: 26895445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab: a novel antiangiogenic agent.
    Wadhwa R; Taketa T; Sudo K; Blum-Murphy M; Ajani JA
    Future Oncol; 2013 Jun; 9(6):789-95. PubMed ID: 23718298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.
    Troiani T; Martinelli E; Orditura M; De Vita F; Ciardiello F; Morgillo F
    Expert Opin Investig Drugs; 2012 Jul; 21(7):949-59. PubMed ID: 22612461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab for the treatment of colorectal cancer.
    Coupez D; Hulo P; Touchefeu Y; Bossard C; Bennouna J
    Expert Opin Biol Ther; 2020 Mar; 20(3):219-226. PubMed ID: 31952453
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
    Battaglin F; Dadduzio V; Bergamo F; Manai C; Schirripa M; Lonardi S; Zagonel V; Loupakis F
    Expert Opin Biol Ther; 2017 Oct; 17(10):1297-1308. PubMed ID: 28752777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Options for Second-Line Treatment in Metastatic Colorectal Cancer.
    Lee JJ; Sun W
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):46-54. PubMed ID: 27057668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
    Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
    Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramucirumab in the second-line treatment of metastatic colorectal cancer: a narrative review of literature from clinical trials.
    Chen CP; Ke TW; Cheng R; Wang JY
    Transl Cancer Res; 2020 Sep; 9(9):5645-5654. PubMed ID: 35117928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted inhibition of VEGF receptor 2: an update on ramucirumab.
    Clarke JM; Hurwitz HI
    Expert Opin Biol Ther; 2013 Aug; 13(8):1187-96. PubMed ID: 23803182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy.
    Verdaguer H; Tabernero J; Macarulla T
    Ther Adv Med Oncol; 2016 May; 8(3):230-42. PubMed ID: 27239240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
    Larkins E; Scepura B; Blumenthal GM; Bloomquist E; Tang S; Biable M; Kluetz P; Keegan P; Pazdur R
    Oncologist; 2015 Nov; 20(11):1320-5. PubMed ID: 26446239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.